#India #Bengaluru #Drug Development #Pharma #STEERLife

Innovative Drug Development at STEERLife

Bengaluru, India - STEERLife, the life sciences arm of STEER World, is setting a new standard in the pharmaceutical industry with its advanced approach to drug development and manufacturing. By focusing on potent and complex drug products, STEERLife is tackling one of the most challenging areas in pharmaceutical science.

At the forefront of their innovation is STEERLife's proprietary solvent-free melt fusion technology, a revolutionary continuous processing system designed to eliminate the need for harmful organic solvents that have long plagued the pharmaceutical manufacturing space. This state-of-the-art technology is capable of efficiently handling high-potency and hard-to-develop molecules, making it a game-changer in formulating complex pharmaceuticals. The adoption of such eco-friendly practices not only increases formulation efficiency and safety but also enhances scalability in production.

As a next-generation Contract Research, Development and Manufacturing Organization (CRDMO), STEERLife possesses the capabilities required to move from concept to market for a multitude of drug types. This includes New Chemical Entities (NCEs), hormone therapies, orphan drugs, complex generics (ANDAs), and 505(b)(2) products, underscoring its vital role in simplifying the development and manufacturing challenges faced by global pharmaceutical companies.

Indu Bhushan, CEO and Director of STEERLife, emphasizes the necessity of control, care, and innovation in potent drug development. “Our continuous, solvent-free platform brings all of that together, enabling faster, cleaner, and more scalable development for the world's most demanding therapies,” he states.

Looking ahead, STEERLife is already working on several key drug products expected to enter the market starting 2026. These include generic versions of well-known medications such as ERLEADA® (Apalutamide), XTANDI® (Enzalutamide), VENCLEXTA® (Venetoclax), and LYNPARZA® (Olaparib). Such initiatives reflect the company's confidence in taking on complex, high-barrier drug programs while maintaining high quality standards.

By collaborating closely with partner facilities, STEERLife aims to effectively service major pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA, and Southeast Asia. This strategic positioning allows them to assist leading drug manufacturers in addressing their most significant development challenges.

Moreover, STEERLife has pioneered the transition from batch to seamless continuous processing in India, propelling the evolution of pharmaceutical manufacturing into a more efficient era. This transition empowers clients globally to shorten development timelines, elevate quality benchmarks, and adopt next-generation drug delivery methods.

About STEERLife

STEERLife is a pioneering life sciences company within the STEER World framework, revolutionizing the development and manufacturing landscape of pharmaceuticals. By leveraging cutting-edge continuous processing and proprietary clean technologies, they facilitate faster, greener, and more efficient drug development processes. The company provides a complete spectrum of services to global partners, from formulation and analytical development to technology transfer, regulatory support, and commercial-scale manufacturing.

In conclusion, STEERLife’s advancements in drug development signify a pivotal shift towards more sustainable practices within the pharmaceutical industry. By leading with innovative technologies and a commitment to quality, STEERLife is not just shaping the future of drug manufacturing but also paving the way for a greener tomorrow in healthcare.